Synephrine Natural Adrenergic Agonist: Exhibits Dual Vasoconstrictive and Metabolic Regulating Activities for Cardiovascular and Metabolic Health Stud

  Product Detail  

(1) Research Applications: Used as an analytical standard for content determination, identification, pharmacological experiments, and bioactivity screening; employed in research experiments such as cellular administration, gastric lavage studies, and internal quality control at pharmaceutical manufacturers.

(2) Clinical Applications: As a sympathomimetic agent, it is used to treat circulatory failure, asthma, nasal congestion, and glaucoma, exhibiting vasoconstrictive and blood pressure-raising effects. Clinically, it can be used to counteract hypotension, collapse, and shock during surgery and anesthesia, as well as orthostatic hypotension.

(3) Dietary Supplement Applications: As the primary active component of bitter orange extract, it is widely used in weight management and fat-reduction products as an alternative to ephedrine.

(4) Metabolic Research Applications: Used to study energy expenditure regulation and fat metabolism, and to evaluate its weight-loss effects in animal models of obesity and metabolic syndrome.

1. (1) α-adrenergic agonist activity: Selectively activates α₁-adrenergic receptors, causing vasoconstriction, thereby increasing blood pressure and improving circulatory function.

   (2) Bronchodilator effect: Exhibits a strong bronchodilator effect on the trachea and bronchi, counteracting histamine-induced bronchoconstriction, and is used to relieve asthma symptoms. In anesthetized cats, intravenous injection completely antagonizes histamine-induced bronchoconstriction.

   (3) Promotion of lipolysis and inhibition of lipogenesis: In 3T3-L1 preadipocytes, treatment with 10–50 μM for 8 days reduces lipid droplet accumulation by 30–55% and downregulates the expression of lipogenesis-related genes such as PPARγ and C/EBPα. In normal mice, intraperitoneal injection of 20 mg/kg increases energy expenditure by approximately 15% within 2 hours via α₁-receptor-mediated lipolysis.

   (4) Weight reduction and metabolic improvement: In a high-fat diet-induced obese mouse model, oral administration of 50 mg/kg/day for 6 consecutive weeks reduced body weight by approximately 18%, visceral fat mass by approximately 25%, and improved insulin sensitivity (fasting blood glucose decreased by approximately 22%).

   (5) Promotion of glucose uptake: In L6 skeletal muscle cells, synephrine promotes Glut4-dependent glucose uptake by upregulating AMPK activity, independent of the insulin-stimulated PI3-kinase-Akt pathway.

   (6) Reduces portal vein pressure: In rat models with portal vein ligation or bile duct ligation, oral administration of 1 mg/kg for 8 days significantly reduced portal vein pressure, portal vein blood flow, and cardiac index, while simultaneously increasing mean arterial pressure, total vascular resistance, and portal vein regional vascular resistance.